Abstract: Small molecule inhibitors GP120-mediated HIV infections, methods for identifying the same, and methods and uses employing of these compounds in treatment, inhibition or prevention of HIV infection are provided. The compounds have a structure according to Formula (I), and comprise a pharmacophore functionally corresponding with pharmacophore (I) of FIG. 2.

Abstract: The present invention provides a method of blocking endoplasmic reticulum associated degradation of functional but misfolded proteins.

Abstract: The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.

Abstract: The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.

Abstract: Compositions and methods are provided for treating a disorder characterized by ?-synuclein dysfunction and/or altered lipid metabolism.

Abstract: The present invention provides a method of blocking endoplasmic reticulum associated degradation of functional but misfolded proteins.

Abstract: The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.

Abstract: The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.

Abstract: Provided is a use of a holotoxin to reduce endoplasmic reticulum-associated degradation (ERAD) of misfolded or abnormally folded proteins The holotoxin can thus be used in a method to treat diseases related to ERAD Examples of misfolded proteins that are degraded in the ER include the cystic fibrosis transmembrane conductance regulator (CFTR) delta F508 mutant protein, a misfolded mutant (G268V) of multi-drug resistance 1 (MDR1), and the glucocerebrosidase (GCC) enzyme in Gaucher's disease cells Examples of suitable holotoxins include ricin, shiga toxin, exotoxin A, plasmid-encoded toxin, cholera toxin, and verotoxin 1 (VT1) VT1 is also known as verotoxin A, shiga-like toxin 1, shiga-like toxin 1, or shiga toxin in type 1 A non-toxic inactive VT1 can also be used wherein crucial residues of the A subunit active site are mutated, for example, the mutations Y77S and E167Q

Abstract: Compositions and methods are provided for treating a disorder characterized by ?-synuclein dysfunction and/or altered lipid metabolism.

Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.

Abstract: The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.

Abstract: Hybrid compounds comprising a first domain and a second domain are provided. The first domain and the second domain are preferably covalently linked, and the first domain comprises a domain which is capable of specific binding to Gb3; and the second domain comprising a moiety selected from the group consisting of drug moiety, a nucleic acid, a probe, a polypeptide, and a hook, with the proviso that the second domain is not a verotoxin or a fragment thereof. Methods of preparing and using the hybrid compounds are also provided.

Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.

Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.

Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.

Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.

Abstract: Hybrid compounds comprising a first domain and a second domain are provided. The first domain and the second domain are preferably covalently linked, and the first domain comprises a domain which is capable of specific binding to Gb3; and the second domain comprising a moiety selected from the group consisting of drug moiety, a nucleic acid, a probe, a polypeptide, and a hook, with the proviso that the second domain is not a verotoxin or a fragment thereof. Mehtods of preapring and using the hybrid compounds are also provided.

Abstract: Hybrid compounds comprising a first domain and a second domain are provided. The first domain and the second domain are preferably covalently linked, and the first domain comprises a domain which is capable of specific binding to Gb3; and the second domain comprising a moiety selected from the group consisting of drug moiety, a nucleic acid, a probe, a polypeptide, and a hook, with the proviso that the second domain is not a verotoxin or a fragment thereof. Mehtods of preapring and using the hybrid compounds are also provided.

Abstract: The invention pertains to methods for inhibiting angiogenesis. Diagnostic and therapeutic methods utilizing anti-angiogenic agents which bind Gb3 or CD77, e.g., verotoxins, are provided. Methods for treating multiple drug resistant tumors are also provided.